In vivo pO2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field

Thomas, Stephen R.; Pratt, Ronald G.; Millard, Ronald W.; Samaratunga, Ranasinghage C.; Shiferaw, Yoseph; McGoron, Anthony J.; Tan, Kim K.

doi:10.1016/0730-725x(95)02046-v

Cited by 39 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the extreme hydrophobicity of PFCs ensures that gases are highly soluble, providing molecular amplification of O 2 concentration while ions are repelled and do not perturb the relation (141). Originally, perfluorocarbon emulsion blood substitutes were exploited, and Thomas et al pioneered their application to assess vascular and tissue oxygenation (142,143). Although MR effects could be observed immediately after intravenous administration of PFCs, measurements were subject to flow artifacts (144).…”

Section: Reporter Molecules For Mr Oximetrymentioning

confidence: 99%

Molecular Imaging of Hypoxia

2008

View full text Add to dashboard Cite

Section: Reporter Molecules For Mr Oximetrymentioning

confidence: 99%

Molecular Imaging of Hypoxia

2008

View full text Add to dashboard Cite

“…where A is the anoxic relaxation rate and B represents the sensitivity of the reporter molecule to the paramagnetic contribution of oxygen and the ratio ¼ B/A has been proposed as a sensitivity index [208]. Several PFCs have been used successfully for NMR oximetry and characteristics are summarized in Table 4.…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 99%

“…Thomas et al [382,383] applied 19 F MRI to show the extent of lung filling. Further, by applying relaxation measurements (as described in Section 3.1), they could estimate regional pO 2 in the lungs of mice, rats, dogs, and pigs [208,383]. Various PFCs and PFC emulsions have been introduced into the lung as aerosols, sometimes with animals under forced ventilation, following thorocotomy [383].…”

Section: Passive Reporter Moleculesmentioning

confidence: 99%

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Mason¹

2007

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

“…characteristic R 1 response to P 0 2 and temperature due to Importantly, RI of PFCs is essentially unresponsive to pH, steric effects of 02, as it approaches the molecule [37, 50]. CO 2 , charged paramagnetic ions, mixing with blood, or Characteristics of many reported PFCs are summarized in emulsification [46,[160][161][162][163][164][165][166]. For an emulsion of (Table 6).…”

Section: Fluorinatedp02 Reporter Moleculesmentioning

confidence: 99%

Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy

Mason¹

2005

View full text Add to dashboard Cite

Public reporting burden for this collection of information Is estimated to average 1 hour per response, Including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, ABSTRACT (Maximum 200 Words)Gene therapy holds great promise for treatment of breast cancer. In particular, clinical trials are underway to apply therapeutic genes related to pro-drug activation or to modulate the activity of oncogenes by blocking promoter sites. However, there are major problems in terms of assessing the delivery to target tissue, assessing the uniformity (versus heterogeneity) of biodistribution and determining whether the genes are expressed. We propose to design, evaluate and apply a novel approach to gene activity detection-specifically, using fluorinated substrates of P-galactosidase to reveal gene activity. Our prototype molecule PFONPG (para-fluoro-ortho-nitro-phenyl P3-D-galactopyranoside) is a direct analog of the traditional "yellow' biochemical indicator ONPG (ortho-nitro-phenyl 3-D-galactopyranoside). This shows useful MR characteristics, sensitivity to enzyme activity and ability to enter cells. We will synthesize analogs of this prototype to optimize MR and biological characteristics and explore the feasibility of tailoring the reporter to specific applications, e.g., exploiting P-gal activity to deliver specific physiological reporter molecules such as pH and potentially specific cytotoxic agents. The agents will be rigorously tested in solution, applied to cultured breast cancer cells and ultimately used to examine P-gal activity in vivo in transfected breast tumors in mice and rats. SUBJECT TERMS NUMBER OF PAGESGene therapy, fluorine NMR, P-galactosidase, pH 127 IntroductionGene therapy holds great promise for treatment of breast cancer (1, 2). In particular, clinical trials are underway to apply therapeutic genes related to pro-drug activation or modulation of the activity of oncogenes by blocking promoter sites. However, there are major problems in terms of assessing the delivery to target tissue, assessing the uniformity (versus heterogeneity) of biodistribution and determining whether the genes are expressed. We propose to design, evaluate and apply a novel approach to gene activity detection-specifically, using fluorinated substrates of P3-galactosidase to reveal gene activity. Our prototype molecule PFONPG (para-fluoro-ortho-nitro-phenyl [3-D-galactopyranoside) is a direct analog of the traditional "yellow' biochemical indicator ONPG (ortho-nitro-phenyl 13-D-galactopyranoside).This shows useful MR characteristics, sensitivity to enzyme activity ...

show abstract

In vivo pO2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field

Cited by 39 publications

References 21 publications

Molecular Imaging of Hypoxia

Molecular Imaging of Hypoxia

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy

Contact Info

Product

Resources

About